In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 28, No. 24 ( 2022-07), p. 1949-1965
Abstract:
Trabectedin, a tetrahydroisoquinoline alkaloid, is the first marine antineoplastic agent approved with
special anticancer mechanisms involving DNA binding, DNA repair pathways, transcription regulation and regulation of the tumor microenvironment. It has favorable clinical applications, especially for the treatment of
patients with advanced soft tissue sarcoma, who failed in anthracyclines and ifosfamide therapy or could not receive these agents. Currently, trabectedin monotherapy regimen and regimens of combined therapy with other
agents are both widely used for the treatment of malignancies, including soft tissue sarcomas, ovarian cancer, breast cancer, and non-small-cell lung cancer. In this review, we have summarized the basic information and
some updated knowledge on trabectedin, including its molecular structure, metabolism in various cancers, pharmaceutical mechanisms, clinical applications, drug combination, and adverse reactions, along with prospects
of its possibly more optimal use in cancer treatment.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612828666220526125806
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
SSG:
15,3
Permalink